FGF23 as a Marker of Acute Kidney Injury
Fibroblast Growth Factor-23 as a Marker of Acute Kidney Injury After Partial Nephrectomy
A partial nephrectomy (PN) preserves renal parenchyma with a proper oncology outcome. PN is performed during transitory ischemia to avoid massive bleeding during tumor resection. Nevertheless, the transitory ischemia might cause an acute kidney injury(AKI). AKI diagnose is based on the increase in plasma creatinine concentration and a decrease in urine output. However, both plasma creatinine concentration and diuresis are useful for the diagnose, but not in the detection of the risk patients. Therefore, there is considerable interest to find a biomarkers of kidney injury that allow clinicians to predict the development of AKI. Hence, we propose Fibroblastic Growth Factor-23 (FGF23) as a novel early biomarker to detect patients in risk to develop postoperative AKI after a PN.
We will conduct an observational and prospective study in three different groups of patients: PN gropup, patients who underwent PN with a transient and controlled renal ischemia injury using a renal artery clamping; Hemicolectomy (HC) group, patients as non-renal ischemia surgery controls, with similar demographic characteristics, but submitted to HC; and Nephrolithotomy (NL) group, patients who underwent NL, as a control of kidney surgery with physical injury.
In each patient, a time curve of plasmatic creatinine, blood urea nitrogen (BUN), and FGF23 were measure.
Our study aims to describe the role of FGF23 as an early biomarker of AKI after PN, where patients are exposed to a controlled ischemic injury.
調査の概要
研究の種類
入学 (予想される)
連絡先と場所
研究場所
-
-
-
Santiago、チリ
- 募集
- Hospital Clinic Universidad de Chile
-
コンタクト：
- Nicolas J Valls, MD
- 電話番号：+56933741332
- メール：nvallsj@hotmail.com
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
説明
Inclusion Criteria:
- American Society of Anesthesiology physical status (ASA) I or II.
- Normal preoperative plasma creatinine level
- Baseline estimated glomerular filtration rate (eGFR) > 60 ml/min per 1.73 m2.
Exclusion Criteria:
- History of chronic kidney disease
- Anemia
- Alterations in the parathormone or vitamin D axis
- Pregnant women
- Subjects with concomitant use of nephrotoxic drugs.
研究計画
研究はどのように設計されていますか？
デザインの詳細
コホートと介入
グループ/コホート |
介入・治療 |
|---|---|
|
Partial Nephrectomy (PN)
Patients that will undergo PN with a transient and controlled renal ischemia injury using a renal artery clamping.
|
Plasma levels of FGF-23 will be measured by ELISA
|
|
Hemicolectomy (HC)
Patients who will undergo HC, as non-renal ischemia surgery controls, with similar demographic characteristics, but submitted to HC.
|
Plasma levels of FGF-23 will be measured by ELISA
|
|
Nephrolithotomy (NL)
Patients who undergo NL as non-renal ischemia surgery controls but with kidney physical injury
|
Plasma levels of FGF-23 will be measured by ELISA
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Acute Kidney Injury
時間枠：72 hours
|
Patients that develop postoperative acute kidney injury
|
72 hours
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (予想される)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。